Maitham A. Khajah, Princy M. Mathew, Yunus A. Luqmani
Oncology Research, Vol.25, No.8, pp. 1283-1295, 2017, DOI:10.3727/096504017X14883245308282
Abstract Current mainstream pharmacological options for the treatment of endocrine-resistant breast cancer have limitations in terms of their side effect profile and lack of discrimination between normal and cancer cells. In
the current study, we assessed the responses of normal breast epithelial cells MCF10A, estrogen receptorpositive (ER+
) MCF-7, and ER-silenced pII breast cancer cells to inhibitors (either individually or in combination) of downstream signaling molecules. The expression/activity of ERK1/2, p38 MAPK, and Akt was
determined by Western blotting. Cell proliferation, motility, and invasion were determined using MTT, wound
healing, and Matrigel assays, respectively. Morphological changes… More >
Login
Register
